Aristada is the brand name for the drug aripiprazole monohydrate. It’s an atypical (second‑generation) antipsychotic that the FDA approved in 2013 for treating schizophrenia and acute manic or mixed episodes in bipolar I disorder. Below is a quick‑reference overview of what you need to know if you’re considering or learning about Aristada.
---
What Is It?
| Feature | Details |
|---------|---------|
| Generic name | Aripiprazole monohydrate |
| Drug class | Atypical antipsychotic |
| Brand name | Aristada |
| Form | Oral tablet (usually 10 mg or 15 mg) |
| Manufacturer | Eli Lilly & Co. (and others for the generic) |
| FDA approval | 2013 (schizophrenia & bipolar I) |
Aripiprazole is also available in other brand names (e.g., Abilify) and as a generic. Aristada is simply the name the company used when they first marketed this drug.
---
How Does It Work?
Aripiprazole is a dopamine partial agonist. Unlike classic antipsychotics that block dopamine receptors, aripiprazole binds to D₂ receptors but only partially activates them. This helps:
- Reduce “over‑dopaminergic” symptoms (hallucinations, delusions)
- Avoid excessive dopamine blockade (which can cause movement disorders)
It also has activity at serotonin receptors (5‑HT₂A antagonism and 5‑HT₁A partial agonism), which contributes to its therapeutic profile and side‑effect profile.
---
What It’s Used For
| Indication | Typical use |
|------------|-------------|
| Schizophrenia | Stabilizes psychotic symptoms in adults |
| Bipolar I disorder | Treats acute manic or mixed episodes |
| Adjunctive therapy | Occasionally added to other antipsychotics for resistant symptoms |
Important: It is not approved for depression, ADHD, or anxiety, and it’s not a first‑line choice for many of those conditions.
---
Typical Dosing (Adults)
NOTE: Dosing should always be guided by a prescriber. The numbers below are general ranges.
| Condition | Starting Dose | Maintenance Dose |
|-----------|---------------|-------------------|
| Schizophrenia | 10 mg once daily | 10–30 mg/day |
| Bipolar I (mania) | 10 mg once daily | 10–15 mg/day (up to 30 mg for more severe mania) |
| Adjunctive | 10–15 mg/day | Up to 30 mg/day |
- Titration: Increase by 5–10 mg increments every 2–4 weeks if needed.
- Switching: If you’re moving from another antipsychotic, a taper‑in schedule is recommended to minimize withdrawal or rebound symptoms.
---
Common Side Effects
| Category | Examples |
|----------|----------|
| Metabolic | Weight gain, increased appetite, mild blood glucose changes |
| Movement | Akathisia (restlessness), tremor, dystonia (rare) |
| CNS | Dizziness, sedation, headache |
| GI | Nausea, constipation |
| Others | Dry mouth, blurred vision, increased cholesterol |
Aripiprazole is often cited as having a lower risk of extrapyramidal symptoms (EPS) compared to older antipsychotics, but akathisia is still common.
---
Serious Risks & Precautions
| Risk | What to Watch For |
|------|--------------------|
| Neuroleptic Malignant Syndrome (NMS) | Fever, rigidity, autonomic instability – seek emergency help if any appear |
| Tardive Dyskinesia | Involuntary movements – monitoring is recommended, especially with long‑term use |
| QT Prolongation | Rare, but monitor ECG if you have heart disease or are on other QT‑prolonging drugs |
| Suicidality | Especially in younger adults – monitor mood changes, suicidal thoughts |
| Severe Hypersensitivity | Rash, anaphylaxis – rare but possible |
| Diabetes & Lipid Changes | Periodic fasting glucose and lipid panels may be warranted |
Contraindications
- Known hypersensitivity to aripiprazole or any excipients
- Severe liver disease (since aripiprazole is metabolized in the liver)
- Concomitant use with other drugs that strongly inhibit CYP2D6 unless the prescribing info specifically advises against it
---
Drug Interactions
| Drug Class | Interaction |
|------------|-------------|
| CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, cimetidine) | ↑ aripiprazole levels – may increase side effects |
| CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin) | Can alter levels – adjust dose accordingly |
| Other antipsychotics | Risk of additive side effects (e.g., QT prolongation, sedation) |
| Antidepressants | May increase risk of serotonin syndrome when combined with MAOIs or certain SSRIs |
| Alcohol | Can increase sedation and CNS depression |
Always disclose all medications, supplements, and herbal products to your prescriber.
---
Pharmacokinetics (Quick Facts)
- Bioavailability: ~80 % after oral ingestion
- Absorption: Peak plasma levels ~5–7 h after dosing
- Distribution: Highly protein‑bound (~95 %); large volume of distribution
- Metabolism: Primarily CYP2D6 and CYP3A4; metabolite dehydroaripiprazole is active
- Half‑life: ~75 h (steady‑state achieved after ~2–3 weeks)
- Elimination: Mainly via feces (≈70 %) and urine (≈20 %)
---
What to Tell Your Doctor
- History of EPS or movement disorders (e.g., tardive dyskinesia)
- Cardiac issues (especially QT prolongation) or electrolyte abnormalities
- Metabolic concerns (diabetes, high cholesterol)
- Any concurrent medications (especially those affecting CYP2D6/CYP3A4)
- Pregnancy or breastfeeding status (aripiprazole is category D – potential risk)
---
Bottom Line
Aristada (aripiprazole) is a well‑studied, generally well‑tolerated antipsychotic that offers a different mechanism of action compared to older drugs. It’s especially useful when you need a balance between symptom control and a lower likelihood of severe movement side effects. As with any medication, the key to success is close communication with your healthcare provider, routine monitoring, and being mindful of the common side‑effect profile.
If you’re considering Aristada, schedule a detailed discussion with your prescriber to confirm the right dose, watch for interactions, and plan monitoring. And remember: never adjust your dose or stop taking the medication without professional guidance.